- Home
- OCUL vs CNTA Comparison
OCUL vs CNTA Comparison
Compare OCUL & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- CNTA
- Stock Information
- Founded
- OCUL 2006
- CNTA 2020
- Country
- OCUL United States
- CNTA United Kingdom
- Employees
- OCUL N/A
- CNTA N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- CNTA Health Care
- Exchange
- OCUL Nasdaq
- CNTA Nasdaq
- Market Cap
- OCUL 2.3B
- CNTA 2.3B
- IPO Year
- OCUL 2014
- CNTA 2021
- Fundamental
- Price
- OCUL $11.26
- CNTA $22.98
- Analyst Decision
- OCUL Strong Buy
- CNTA Strong Buy
- Analyst Count
- OCUL 9
- CNTA 8
- Target Price
- OCUL $22.13
- CNTA $31.29
- AVG Volume (30 Days)
- OCUL 3.2M
- CNTA 1.2M
- Earning Date
- OCUL 11-13-2025
- CNTA 11-11-2025
- Dividend Yield
- OCUL N/A
- CNTA N/A
- EPS Growth
- OCUL N/A
- CNTA N/A
- EPS
- OCUL N/A
- CNTA N/A
- Revenue
- OCUL $56,664,000.00
- CNTA $15,000,000.00
- Revenue This Year
- OCUL N/A
- CNTA N/A
- Revenue Next Year
- OCUL $18.87
- CNTA N/A
- P/E Ratio
- OCUL N/A
- CNTA N/A
- Revenue Growth
- OCUL N/A
- CNTA 118.88
- 52 Week Low
- OCUL $5.79
- CNTA $9.60
- 52 Week High
- OCUL $13.85
- CNTA $24.57
- Technical
- Relative Strength Index (RSI)
- OCUL 41.98
- CNTA 59.26
- Support Level
- OCUL $10.85
- CNTA $22.71
- Resistance Level
- OCUL $11.77
- CNTA $23.67
- Average True Range (ATR)
- OCUL 0.72
- CNTA 1.01
- MACD
- OCUL -0.16
- CNTA -0.24
- Stochastic Oscillator
- OCUL 28.63
- CNTA 42.34
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.